ArticleAntibiotics (Basel, Switzerland)2021
Colistin and Carbapenem-Resistant
Article in Antibiotics (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 21 citations in OpenAlex.
- Comprehensive Molecular Characterization of Extensively Drug-ResistantPharmaceuticals (Basel, Switzerland) · 2026Article
- Genomic and GWAS-Based Insights into Antimicrobial Resistance inAntibiotics (Basel, Switzerland) · 2026Article
- Investigating the types of microorganisms causing cerebrospinal fluid shunt infection in King Abdullah University Hospital in Jordan.Qatar medical journal · 2025Article
- Colistin Resistance Mechanism and Management Strategies of Colistin-ResistantPathogens (Basel, Switzerland) · 2024Review
- Genomic Insights of Multidrug-Resistant Enterococcus faecalis and Acinetobacter baumannii Isolated from a Sepsis Patient with Pauci-Immune Crescentic Glomerulonephritis, India.Current microbiology · 2024Article
- Four New Sequence Types and Molecular Characteristics of Multidrug-ResistantAntibiotics (Basel, Switzerland) · 2024Article
- TracingMicroorganisms · 2024Article
- Enhancing effect of natural adjuvant, panduratin A, on antibacterial activity of colistin against multidrug-resistant Acinetobacter baumannii.Scientific reports · 2024Article
- Article
- Colistin Resistance inAntibiotics (Basel, Switzerland) · 2023Review
- Carbapenemase genes distribution in clonal lineages ofFrontiers in cellular and infection microbiology · 2023Article
- Genomic Analysis of Antibiotics Resistance in Pathogens.Antibiotics (Basel, Switzerland) · 2022Article
- Engineering of lysin by fusion of antimicrobial peptide (cecropin A) enhances its antibacterial properties against multidrug-resistantFrontiers in microbiology · 2022Article
- Whole genome sequence of pan drug-resistant clinical isolate of Acinetobacter baumannii ST1890.PloS one · 2022Article
- Emergence of high colistin resistance in carbapenem resistantFrontiers in pharmacology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Resistance to the last-line antibiotics against invasive Gram-negative bacterial infection is a rising concern in public health. Multidrug resistant (MDR)
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.